The Medicines Company (NASDAQ:MDCO)
CAPS Rating:
A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.
Taking it to the street
A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Hearing good things from cardiologists about Angiomax. recent support from journals. Could be a combo w/BMY for cath patients. No debt on board, so if this drug hits.......the stock could go out of the yard.
My mistake about combo w/BMY. Recent non-approval for use in ER is somewhat bogus, as we are using it for cath pts already (off-label) and the penetration is roughly around 40% of cath pts right now. Its better than heparin as far as bleeding complications b/c half-life so short, requiring less intensive and cheaper post-procedure care. This product has room to grow over next 2-3 yrs and could hit 1 billion in sales if the FDA gets off their pedestal.